IL2 and ovarian carcinoma: illustrated that CXCL13 is capable of heightening response to immunotherapy in ovarian cancer mouse model by increasing infiltration level of CD8+T cells and secretion level of GZMB, IFN‐γ and IL‐2.[43] Accompanying stronger anticancer response, combination therapy further upsets existed immune feedback loop, which probably leads to severe side effects.